Introduction
Multiple sclerosis (MS), a chronic inflammatory demyelinating disorder of the central nervous system, is one of the most frequent causes of nontraumatic neurological disability in young adults. Although inflammation, demyelination and axonal degeneration are well characterized during the course of the disease, 1 a comprehensive understanding of the etiology of MS and the mechanistic pathways leading to disease progression are still lacking. It is widely accepted, though, that MS is a complex and heterogeneous disease resulting from the combination of genetic and environmental risk factors. 2, 3 The main genetic determinant described to date is the major histocompatibility complex region identified more than 30-years ago; 4 the HLA (human leucocyte antigen)-DRB1*15:01 allele confers by far the strongest effect on MS susceptibility. 5 Nonetheless, this is not the unique contributing factor to disease risk, and classical linkage and association studies have pointed to an increasing series of non-major histocompatibility complex genes involved in MS predisposition. Moreover, during the past 2 years, genome-wide association studies (GWAS) have yielded an extraordinary wealth of data that provided interesting clues about the pathogenesis of immunemediated diseases including rheumatoid arthritis, inflammatory bowel disease, type I diabetes among others. 6, 7 Certain pathogenic mechanisms were unambiguously highlighted, for instance, the importance of autophagy and innate immunity as critical components of the altered host-bacterial interactions leading to Crohn's disease. 8 Furthermore, previously unsuspected genes were found to influence susceptibility in some immune-mediated diseases although the individual effect of each locus revealed usually modest genetic size effects, consistent with the polygenic basis of these complex traits. 9 Considerable overlap was also shown to exist between loci identified as risk factors for the different autoimmune diseases, suggesting a shared influence of noteworthy genes on the breakdown of self-tolerance.
In 2007, the International MS Genetics Consortium performed the first GWAS in MS 10 and identified the involvement of several genes such as the cytokine receptor encoding genes IL2RA and IL7R, in keeping with the autoimmune nature of the disease. The study analyzed more than 12000 subjects in two phases for replication purposes. Another GWAS subsequently performed by the Australian and New Zealand MS Genetics Consortium 11 confirmed some of the genes previously found, such as IL7R, IL2RA, EVI5-RPL5, CLEC16A or CD58, which have been consistently validated in independent studies. [11] [12] [13] Another GWAS was conducted in 1000 MS patients and an age/gender-matched control group.
14 In contrast to the International MS Genetics Consortium study, the latter focused on the discovery of genes not only associated with MS susceptibility, but also with the clinical phenotype. Our purpose with the present work is to replicate the association with overall MS of the top (non-HLA) risk markers identified in the GWAS conducted by Baranzini and collaborators.
14 One should bear in mind that even a relative large GWAS has a rather low power to detect any specific marker. The accepted measure of genome-wide significance (P ¼ 10 À7 -10 À8 , equivalent to a P ¼ 0.05 for a classical epidemiological study in which only one hypothesis is being tested) warrants corroboration of the relevant genes. 15 Even more so when the proposed associations show less stringent support (Pp10
À5
), the reported loci need replication in additional data sets before they can be considered reliable susceptibility markers. With this aim, a total of 2863 MS patients and 2930 healthy controls from Spain, matched by age, gender and ethnicity were compared in a case-control study.
Results
We selected the top (non-HLA) MS risk markers identified in the GWAS conducted by Baranzini et al.
14
These polymorphisms were genotyped in a Spanish cohort of MS patients (n ¼ 2863) and controls (n ¼ 2930) (see Table 1 for the characteristics of the study group). No marker showed deviation from Hardy-Weinberg equilibrium. There were no statistically significant differences in genotyping calling rates between cases and controls for any of these markers.
As shown in Table 2 , the analysis of the Spanish samples solely replicated the reported association of rs9523762 in the GPC5 gene with MS susceptibility (G allele: P ¼ 1.6 Â 10
À5
, odds ratio ¼ 1.23, 95% confidence interval ¼ 1.12-1.36). No other associations with the pathogenesis of the disease were detected in the study population. Statistical power allows detecting the magnitude of the previously published effects for each single-nucleotide polymorphism (SNP) except for rs16914086 (Table 2) . Similar results were also obtained by logistic regression analyses adjusted by covariates (gender and HLA-DRB1*15:01, 
Discussion
GWA studies explore the entire human genome unconstrained by previous hypothesis about the nature of genes that influence complex diseases. However, the massive number of statistical tests performed in this approach presents an unprecedented potential for false positive results. 16 Often, GWAS use multistage designs to warrant replication of the original findings, otherwise, the confirmation of association signals through largescale replication is recommended. 15 With this limitation in mind, our aim with the present work was to corroborate the best-associated variants identified in the GWAS by Baranzini et al. 14 The authors defined top-scoring (non-HLA) markers associated with global MS susceptibility, all of them with modest effects on disease risk, by performing the screen of allele frequencies for 551642 SNPs in 978 MS cases and 883 controls. Our scan of these markers in an independent collection of 2863 MS cases and 2930 controls revealed replication of the GPC5 polymorphism studied, but no other best hit reached significance. Glypicans regulate cell-cell signaling and are expressed during brain neurogenesis 17 and they have been found in MS active plaques. 18 Other polymorphisms in the GPC5 gene have been consistently associated with response to interferon (IFN)-b in MS patients; 19, 20 however, these polymorphisms (rs10492503, rs9523554/rs9301789) and the one showing an effect in the present work (rs9523762) are not genetic proxies (r 2 Replication of top markers of a genome-wide association study ML Cavanillas et al Replication of top markers of a genome-wide association study ML Cavanillas et al tively). Given the fact that GPC5 is associated with MS susceptibility, as well as with the response to IFN-b therapy, it is tantalizing to speculate that the IFN type I pathway might have a role in the pathogenesis of the disease, at least in a subgroup of patients. Recently, GPC5 rs9523762 results were published in African Americans, 21 though no significant association with MS was reached (P ¼ 0.154). Interestingly, the risk allele in African Americans (G) is the same as the one now found to be associated with MS susceptibility in Spain, whereas the opposite allele (A) was originally described to be associated in Caucasian individuals. 21 The meta analysis of both GPC5 studies in Spanish and African American subjects (heterogeneity P ¼ 0.43; I 2 ¼ 0%) yielded a P MÀH o0.00001; odds ratio MÀH (95% confidence inteval) ¼ 0.83 (0.76-0.90). The initially reported odds ratio (1.361) reflects an effect stronger than this one. This well-described phenomenon (the so called 'winner's curse') would justify a lack of replication for the other best-associated markers, provided that the original effects were overestimated. Nonetheless, the size of our collections would allow us to detect effects even smaller than those originally reported, as indicated in Table 2 , when applying the standard threshold of statistical power (80%, a ¼ 0.05). Thus, evidence is mounting for the GPC5 gene being a genuine susceptibility factor for MS. Recently, polymorphisms within this gene have been associated with sudden cardiac arrest 22 or lung cancer in non-smokers, 23 and variants in the adjacent GPC6 gene have also been associated with primary sclerosing cholangitis. 24 Both genes span around 3 Mb in 13q32, a chromosomal region where genomic amplification has been reported in different types of tumors. 25 Further research is warranted to ascertain the role of these genes in the different pathologies.
Two polymorphisms in the CSMD1 gene were among the top associated markers originally found in the GWAS by Baranzini et al.
14 : rs1529316 and rs2049306 (r 2 ¼ 0.84). Another polymorphism in this gene, rs1611927, was recently found associated in a meta-analysis that included data of the performed GWAS in MS. 26 However, the latter variant presents very low correlation with the two former CSMD1 variants (r 2 ¼ 0.012 and r 2 ¼ 0.02, respectively) and therefore, the meta-analysis results do not seem to replicate the associations initially described.
Concordantly, in our population no replications were obtained for the two closely related CSMD1 polymorphisms already mentioned.
One potential explanation for the observed discrepancy between our study and Baranzini's original data could reside in the non-replicated associations being false-positive results. Alternatively, the linkage disequilibrium between the causal variants and the markers associated in each locus might be different depending on the population studied. An additional possibility is that what appears to be a homogeneous MS phenotype might, in fact, be due to distinct etiologies in different MS patients in such a way that a genuine effect pertinent to a specific category of patients could pass undetected when analyzing the whole collection. 27 Finally, the question of population-specific MS risk genes is as yet unanswered. Given the lower prevalence of MS in the Mediterranean areas including Spain (prevalence of 0.0008, http://www.mult-sclerosis.org/prev_tab.html), it remains to be seen whether the same gene-environment interactions or genetic penetrance have a role in MS irrespective of geographic/ethnical background. Stratification by gender, clinical forms or by the well-known susceptibility factor HLA-DRB1*1501 did not provide clues about any specific effects in a subgroup of patients; nonetheless, the markers presently studied were reported to influence overall MS risk. Research should be undertaken to examine the heterogeneity in the causes of MS; considering a more refined categorization of cases might change the output. 28 The GWAS reveal the complex nature of MS and the current number of loci associated with MS represents only a small fraction of the disease heritability, so there must be additional genetic contributions to discover. 29 As GWAS focus on common genetic variation across the genome, disease-associated low-frequency polymorphisms or else copy-number variants would have not been detected with this approach. Moreover, the etiologic variants are presently ascertained in only a minority of loci; therefore, with the fine-mapping of the confirmed genetic loci and the identification of the etiologic risk variants, a larger effect might be ascribed to the susceptibility genes. New avenues to the identification of susceptibility genes involved in the pathogenesis of a specific disease could be opened through the analysis of the interactions among genes, a strategy that has already delivered interesting results. 30, 31 Certainly, although the most immediate use of GWAS results remains the advance in the understanding of biologic pathways of disease causation, 5,32 a robust replication is a crucial first step in this direction and to develop suitable therapeutic strategies in the future.
33,34

Materials and methods
The entire data set studied consisted of 2863 MS patients diagnosed according to Poser's criteria 35 and 2930 healthy controls, mostly blood donors and staff, matched by age, gender, ethnicity and place of recruitment. Patients and controls were included in the study after written informed consent and were consecutively recruited as follows: 460 cases and 462 controls from Hospital Vall d'Hebron and Hospital Clinic (Barcelona, Spain); 535 cases and 536 controls from Hospital Clínico SNPs were genotyped using the iPLEX Sequenom MassARRAY platform in the Spanish National Genotyping Center (CEGEN, Santiago de Compostela, www.cegen. org). All DNA was received in the CEGEN centre for genotyping in 96-well plates; the concentration of doublestranded DNA was assessed using PicoGreen (Molecular Probes, Inc., Eugene, OR, USA). As quality control, two trios of CEPH samples were genotyped (CEPH Na10830, Na10831, Na12147, Na10860, Na10861 and Na11984). The genotypes of these samples resulted in no detection of mendelian inconsistencies and corresponded with the ones deposited in HapMap. On the other hand, a 10% of random samples were subjected to re-genotyping. The resulting data were concordant with an average accuracy of 499.9%. We performed quality filtering of both samples and SNPs to ensure robust association testing. We analyzed only SNPs with high quality data (495% genotype call rate and Hardy-Weinberg equilibrium P-value40.05 in healthy control subjects). The polymorphism rs397020 did not satisfy the quality control and therefore it was excluded from further analysis and rs908821 did not conform to the chip design restrictions. The homogeneity of DNA samples from different locations and Mantel-Haenszel analyses performed to investigate the association of previously reported SNPs (Review Manager (RevMan) 5.0 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008)) are shown in Supplementary Tables 1 and 2 . The present work has been designed as a replication study; therefore P-values are not corrected. Power calculations were performed by using http://www.sph.umich.edu/ csg/abecasis/cats/.
